고객센터
찾아오시는길

HOME > 회원마당 > 보도자료보도자료

Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

관리자 | 2020.04.06 10:47 | 조회 70

Aging and disease  http://www.aginganddisease.org/images/dao.gif  2020Vol. 11 http://www.aginganddisease.org/images/dao.gif Issue (2) : 216-228     DOI: 10.14336/AD.2020.0228

 

Orginal Article

http://www.aginganddisease.org/images/hyp_en.jpg

Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

Zikuan Leng1,5, Rongjia Zhu2, Wei Hou3, Yingmei Feng3, Yanlei Yang4, Qin Han2, Guangliang Shan2, Fanyan Meng1, Dongshu Du1, Shihua Wang2, Junfen Fan2, Wenjing Wang3, Luchan Deng2, Hongbo Shi3, Hongjun Li3, Zhongjie Hu3, Fengchun Zhang4, Jinming Gao4, Hongjian Liu5,*, Xiaoxia Li6, Yangyang Zhao2, Kan Yin6, Xijing He7, Zhengchao Gao7, Yibin Wang7, Bo Yang8, Ronghua Jin3,*, Ilia Stambler9,10,11, Lee Wei Lim9,10,12, Huanxing Su9,10,13, Alexey Moskalev9,10,14, Antonio Cano9,10,15, Sasanka Chakrabarti16, Kyung-Jin Min9,10,17, Georgina Ellison-Hughes9,10,18, Calogero Caruso9,10,19, Kunlin Jin9,10,20,*, Robert Chunhua Zhao1,2,9,10,*

1School of Life Sciences, Shanghai University, Shanghai, China.
2Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
3Beijing YouAn Hospital, Capital Medical University, Beijing, China.
4Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
5Department of Orthopaedics, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
6Institute of Stem Cell and Regeneration Medicine, School of Basic Medicine, Qingdao University, Shandong, China.
7Department of Orthopaedics, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China.
8Department of Neurosurgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
9The Executive Committee on Anti-aging and Disease Prevention in the framework of Science and Technology, Pharmacology and Medicine Themes under an Interactive Atlas along the Silk Roads, UNESCO, Paris, France.
10International Society on Aging and Disease, Fort Worth, Texas, USA.
11The Geriatric Medical Center "Shmuel Harofe", Beer Yaakov, affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
12School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
13Institute of Chinese Medical Science, University of Macau, Taipa, Macau, China.
14Institute of Biology, Komi Science Center of Russian Academy of Sciences, Syktyvkar, Russia.
15Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain.
16Maharishi Markandeshwar Deemed University, Mullana-Ambala, India.
17Department of Biological Sciences, Inha University, Incheon, South Korea.
18Faculty of Life Sciences & Medicine, King's College London, London, UK.
19Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy.
20University of North Texas Health Science Center, Fort Worth, TX76107, USA.

 

 

·         Abstract

·         Figures/Tables

·         References

·         Supplementary Material

·         Related Articles

·         Metrics

Download: PDF(1473 KB)   HTML
Export: BibTeX | 
EndNote | Reference Manager | ProCite | RefWorks    

Abstract  

A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients without observed adverse effects. The pulmonary function and symptoms of these seven patients were significantly improved in 2 days after MSC transplantation. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes were increased, the C-reactive protein decreased, and the overactivated cytokine-secreting immune cells CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared in 3-6 days. In addition, a group of CD14+CD11c+CD11bmid regulatory DC cell population dramatically increased. Meanwhile, the level of TNF-α was significantly decreased, while IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression profile showed MSCs were ACE2- and TMPRSS2- which indicated MSCs are free from COVID-19 infection. Thus, the intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition.

Keywords COVID-19      ACE2 negative      mesenchymal stem cells      cell transplantation      immunomodulation      function recovery     

Corresponding Authors: Liu Hongjian,Jin Ronghua,Jin Kunlin,Zhao Robert Chunhua   

About author: #

These authors contributed equally to this work.

Just Accepted Date: 29 February 2020   Issue Date: 13 March 2020

0

Service

http://www.aginganddisease.org/images/arrow.jpg

E-mail this article

양식의

양식의 아래

http://www.aginganddisease.org/images/arrow.jpg

E-mail Alert

http://www.aginganddisease.org/images/arrow.jpg

RSS

Articles by authors

http://www.aginganddisease.org/images/arrow.jpg

Leng Zikuan

http://www.aginganddisease.org/images/arrow.jpg

Zhu Rongjia

http://www.aginganddisease.org/images/arrow.jpg

Hou Wei

http://www.aginganddisease.org/images/arrow.jpg

Feng Yingmei

http://www.aginganddisease.org/images/arrow.jpg

Yang Yanlei

http://www.aginganddisease.org/images/arrow.jpg

Han Qin

http://www.aginganddisease.org/images/arrow.jpg

Shan Guangliang

http://www.aginganddisease.org/images/arrow.jpg

Meng Fanyan

http://www.aginganddisease.org/images/arrow.jpg

Du Dongshu

http://www.aginganddisease.org/images/arrow.jpg

Wang Shihua

http://www.aginganddisease.org/images/arrow.jpg

Fan Junfen

http://www.aginganddisease.org/images/arrow.jpg

Wang Wenjing

http://www.aginganddisease.org/images/arrow.jpg

Deng Luchan

http://www.aginganddisease.org/images/arrow.jpg

Shi Hongbo

http://www.aginganddisease.org/images/arrow.jpg

Li Hongjun

http://www.aginganddisease.org/images/arrow.jpg

Hu Zhongjie

http://www.aginganddisease.org/images/arrow.jpg

Zhang Fengchun

http://www.aginganddisease.org/images/arrow.jpg

Gao Jinming

http://www.aginganddisease.org/images/arrow.jpg

Liu Hongjian

http://www.aginganddisease.org/images/arrow.jpg

Li Xiaoxia

http://www.aginganddisease.org/images/arrow.jpg

Zhao Yangyang

http://www.aginganddisease.org/images/arrow.jpg

Yin Kan

http://www.aginganddisease.org/images/arrow.jpg

He Xijing

http://www.aginganddisease.org/images/arrow.jpg

Gao Zhengchao

http://www.aginganddisease.org/images/arrow.jpg

Wang Yibin

http://www.aginganddisease.org/images/arrow.jpg

Yang Bo

http://www.aginganddisease.org/images/arrow.jpg

Jin Ronghua

http://www.aginganddisease.org/images/arrow.jpg

Stambler Ilia

http://www.aginganddisease.org/images/arrow.jpg

Lim Lee Wei

http://www.aginganddisease.org/images/arrow.jpg

Su Huanxing

http://www.aginganddisease.org/images/arrow.jpg

Moskalev Alexey

http://www.aginganddisease.org/images/arrow.jpg

Cano Antonio

http://www.aginganddisease.org/images/arrow.jpg

Chakrabarti Sasanka

http://www.aginganddisease.org/images/arrow.jpg

Min Kyung-Jin

http://www.aginganddisease.org/images/arrow.jpg

Ellison-Hughes Georgina

http://www.aginganddisease.org/images/arrow.jpg

Caruso Calogero

http://www.aginganddisease.org/images/arrow.jpg

Jin Kunlin

http://www.aginganddisease.org/images/arrow.jpg

Zhao Robert Chunhua

 

Cite this article:   

Leng Zikuan,Zhu Rongjia,Hou Wei, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia[J]. Aging and disease, 2020, 11(2): 216-228.

URL:  

http://www.aginganddisease.org/EN/10.14336/AD.2020.0228     OR

 

 

보도자료
번호 제목 글쓴이 조회 날짜
125 "줄기세포로 코로나19로 손상된 폐 치료가능" 학계 주장에 눈길 관리자 225 2020.04.20
124 줄기세포로 '코로나19' 치료 가능할까... 관리자 192 2020.04.20
123 [포스트 코로나]이희영 대한줄기세포치료학회장, 관리자 176 2020.04.20
122 줄기세포 배양문제 해결? 코로나19 치료 해답 이희영 회장, “의사 자율.. 관리자 185 2020.04.20
121 '줄기세포 치료 활성화' 첨단재생바이오법 입법예고 관리자 185 2020.04.20
120 [현장에서] ‘백신·치료제보다 줄기세포’ 코로나19, 맹장 수술비용으로 .. 관리자 124 2020.04.20
119 줄기세포치료학회 관리자 124 2020.04.20
118 "긴급한 코로나19 환자에 줄기세포 치료 적용해야" 관리자 117 2020.04.20
117 "변이 많은 코로나19, 줄기세포 치료가 대안" 관리자 131 2020.04.20
116 "줄기세포로 손상된 폐 재생…코로나19 치료 효과적" 관리자 123 2020.04.20
115 이희영 회장 “치료제·백신 개발 변수많아… 줄기세포 치료가 우선” Ss 143 2020.04.20
114 [TF사진관] '줄기세포 코로나19 치료 가능하다' Ss 139 2020.04.20
113 줄기세포 주사, 면역력 강화에 도움 줄 수 있어 Ss 217 2020.04.14
112 줄기세포 코로나19 치료제 후보 급부상 Ss 255 2020.04.14
111 지방으로 코로나를? 한인 2세, 줄기세포 치료제 눈길 Ss 208 2020.04.14
110 치료제 없는 코로나19…국내 의료진의 긴급처방은? Ss 96 2020.04.14
>> Transplantation of ACE2- Mesenchymal Ste.. 관리자 71 2020.04.06
108 Mesenchymal stem cells and management of.. 관리자 67 2020.04.06
107 Stem cells may give a respite to COVID-1.. 관리자 65 2020.04.06
106 Stem Cell Therapy for COVID-19 Is Gainin.. 관리자 60 2020.04.06